LaNova Medicines Announces IND Approval of LM-24C5 by US FDA
-
2023-09-28
-
Share:
SHANGHAI, September 28th, 2023 – LaNova Medicines Ltd. announced that the investigational new drug (IND) of LM-24C5, an anti-CEACAM5/4-1BB bispecific antibody, has been approved by the US Food and Drug Administration (FDA).